| Technologies for detecting falsified and substandard drugs in low and middle-income countries S Kovacs, SE Hawes, SN Maley, E Mosites, L Wong, A Stergachis PloS one 9 (3), e90601, 2014 | 188 | 2014 |
| Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis J Gutman, S Kovacs, G Dorsey, A Stergachis, FO Ter Kuile The Lancet infectious diseases 17 (2), 184-193, 2017 | 109 | 2017 |
| Treating Severe Malaria in Pregnancy: A review of the evidence SA Kovacs S, Rijken M Drug Safety 38 (2), 165-181, 2015 | 78 | 2015 |
| Deconstructing the differences: a comparison of GBD 2010 and CHERG’s approach to estimating the mortality burden of diarrhea, pneumonia, and their etiologies SD Kovacs, K Mullholland, J Bosch, H Campbell, MH Forouzanfar, I Khalil, ... BMC infectious diseases 15, 1-15, 2015 | 59 | 2015 |
| Patterns and Predictors of HIV/STI Risk Among Latino Migrant Men in a New Receiving Community P Kissinger, S Kovacs, C Anderson-Smits, N Schmidt, O Salinas, ... AIDS and behavior 16 (1), 199-213, 2012 | 55 | 2012 |
| Wastewater testing and detection of poliovirus type 2 genetically linked to virus isolated from a paralytic polio case—New York, March 9–October 11, 2022 AB Ryerson MMWR. Morbidity and Mortality Weekly Report 71, 2022 | 44 | 2022 |
| The safety of artemisinin derivatives for the treatment of malaria in the 2nd or 3rd trimester of pregnancy: a systematic review and meta-analysis SD Kovacs, AM van Eijk, E Sevene, S Dellicour, NS Weiss, S Emerson, ... PLoS One 11 (11), e0164963, 2016 | 35 | 2016 |
| Updated characterization of post‐OPV cessation risks: Lessons from 2019 serotype 2 outbreaks and implications for the probability of OPV restart DA Kalkowska, MA Pallansch, SL Cochi, SD Kovacs, SGF Wassilak, ... Risk Analysis 41 (2), 320-328, 2021 | 31 | 2021 |
| Patterns and predictors of multiple sexual partnerships among newly arrived Latino migrant men MD Althoff, C Anderson-Smits, S Kovacs, O Salinas, J Hembling, ... AIDS and Behavior 17, 2416-2425, 2013 | 24 | 2013 |
| The safety of atovaquone-proguanil for the prevention and treatment of malaria in pregnancy: A systematic review KL Andrejko, RC Mayer, S Kovacs, E Slutsker, E Bartlett, KR Tan, ... Travel medicine and infectious disease 27, 20-26, 2019 | 23 | 2019 |
| Review of use of inactivated poliovirus vaccine in campaigns to control type 2 circulating vaccine derived poliovirus (cVDPV) outbreaks CF Estivariz, SD Kovacs, O Mach Vaccine 41, A113-A121, 2023 | 18 | 2023 |
| Modeling poliovirus transmission in Borno and Yobe, northeast Nigeria DA Kalkowska, R Franka, J Higgins, SD Kovacs, JC Forbi, SGF Wassilak, ... Risk Analysis 41 (2), 289-302, 2021 | 13 | 2021 |
| Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled … AL Wilkinson, K Zaman, M Hoque, CF Estivariz, CC Burns, ... The Lancet Infectious Diseases 23 (9), 1062-1071, 2023 | 11 | 2023 |
| Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine A Voorman, H Lyons, C Bennette, S Kovacs, JK Makam, JF Vertefeuille, ... Vaccine 41, A85-A92, 2023 | 10 | 2023 |
| Assessing the immunogenicity of three different inactivated polio vaccine schedules for use after oral polio vaccine cessation, an open label, phase IV, randomized controlled trial K Zaman, SD Kovacs, K Vanderende, A Aziz, M Yunus, S Khan, CJ Snider, ... Vaccine 39 (40), 5814-5821, 2021 | 6 | 2021 |
| Acute wheeze in the pediatric population: case definition & guidelines for data collection, analysis, and presentation of immunization safety data MA Katz, D Marangu, EF Attia, J Bauwens, LJ Bont, A Bulatovic, J Crane, ... Vaccine 37 (2), 392-99, 2019 | 5 | 2019 |
| Donor support for quality assurance and pharmacovigilance of anti-malarials in malaria-endemic countries SD Kovacs, BM Mills, A Stergachis Malaria Journal 16, 1-10, 2017 | 1 | 2017 |
| Modeling the spread of circulating vaccine-derived poliovirus type 2 outbreaks and interventions: A case study of Nigeria Y Sun, P Keskinocak, LN Steimle, SD Kovacs, SG Wassilak Vaccine: X 18, 100476, 2024 | | 2024 |
| A Compartmental Simulation Model to Improve Interventions for Controlling Poliovirus Outbreaks Y Sun, P Keskinocak, LN Steimle, SD Kovacs, SG Wassilak 2023 Winter Simulation Conference (WSC), 1184-1195, 2023 | | 2023 |
| non-inferiority, randomised, controlled trial AL Wilkinson, K Zaman, M Hoque, CF Estivariz, CC Burns, ... | | 2023 |
